Background
Immune cell trafficking, gliosis, and neuroinflammation are fundamental immune responses designed to protect the brain from harm [
1]. Uncontrolled or unregulated neuroinflammation, however, has been implicated as a causative event in many neurodegenerative diseases [
2,
3]. One important facet of the inflammatory response is the signaling cascades used to bring inflammatory cells to the areas of damage or pathology (i.e., chemokines). Interestingly, similar inflammatory cell recruitment responses can be observed across distinct injuries. After significant damage to the brain, brain derived microglia and peripheral derived macrophages are recruited to areas of tissue damage in efforts to reduce pathologic protein accumulation and repair the damage [
4]. Additionally, microglia recruitment around Aβ plaques in Alzheimer’s disease (AD) are commonly observed. In both CTE and AD, chronic signaling through repetitive injuries or failure to remove toxic protein products is hypothesized to result in constant recruitment of inflammatory microglia/macrophage and may perpetuate a chronic neuroinflammatory response and disease propagation.
Recently, it has been observed that the neuroinflammatory response may be involved in the pathogenesis and disease progression of the neurodegenerative disease chronic traumatic encephalopathy (CTE) [
2]. CTE is a progressive tauopathy found in individuals with a history of repetitive head impacts (RHI) typically obtained through playing contact sports such as American football, hockey, soccer, or rugby, in addition to injuries sustained during military service [
5,
6]. Evidence from biomechanical computation, helmet sensor data, and neuropathologic autopsy suggests that blood vessels found in the frontal cortex at the depth of the cortical sulcus are observed to be affected the earliest and most severely in CTE, while other regions, including medial and occipital regions such as the calcarine cortex, were relatively spared [
6‐
9]. The amount of neuroinflammation and severity of pathology has been found to be proportional to the time spent playing contact sports and has been suggested to be an important mechanism of pathogenesis [
2,
10]. Although it is unclear which specific neuroinflammatory factors are involved, there is strong evidence that microglia are highly involved at all levels of disease severity [
2,
11,
12]. Therefore, it would be of interest to better study the signals required to recruit microglia to regions of damage and pathology.
One of the most potent microglia/macrophage chemokines is monocyte chemoattractant protein 1 (MCP1) or more commonly referred to as CCL2 (chemokine (C-C motif) ligand 2) [
13]. CCL2 is produced by many CNS resident cells such as astrocytes, neurons, oligodendrocytes, endothelial cells, and also, microglia themselves. Altered expression of CCL2 or its receptor, CCR2, have been found to play mechanistic roles in a variety of brain pathologies. Loss of CCR2 was found to reduce microglia recruitment and increase Aβ in murine models of AD [
14]. Elevated levels of CCL2 have been found in acute and chronic multiple sclerosis plaques [
15]. Overexpression of CCL2 in experimental stroke models observed increased infarct volume and greater ischemia [
16], while CCL2 deficient mice had less tissue damage after permanent middle cerebral artery occlusion [
17]. Taken together, CCL2 plays an important role in propagating pathology through recruitment of peripheral and central immune cells to the area of injury and initiates an inflammatory response that is often prolonged and harmful.
Overall, we hypothesize that CCL2 will be positively associated with exposure to RHI and be part of the signaling cascade recruiting microglia to regions of damage and neuropathology in CTE. Herein, we investigate CCL2 protein levels across multiple brain regions to determine if there is a regional specific increase that relates to initial tau deposition. Additionally, we test the hypothesis that although CCL2 might be elevated in other tauopathies such as AD, the regional increased observed in CTE will be distinct. Finally, we explore whether there is a differential effect of pathologic proteins, such as hyperphosphorylated tau or Aβ, on CCL2 expression. The work presented here seeks to identify connections between CCL2 and neuropathology that could become future targets for novel therapeutic strategies aimed to prevent pathology before it begins.
Discussion
Here, we have shown that there is increased Iba1+ cell recruitment around pTau containing blood vessels in CTE. When investigating possible recruitment factors, the chemokine CCL2, was observed to correlate with years of playing American football, number of Iba1+ cells, and number of CD68+ neuroinflammatory cells. Further analysis demonstrated protein levels of CCL2 were elevated preferentially in the frontal cortex, a region where CTE pathology can first be observed. CCL2 did not correlate with the NIA-Reagan criteria for AD likelihood in a separate group of cases that lacked a significant history of exposure to head impacts. Analysis of the specific effect of pTau and Aβ
42 demonstrated that pTau correlated with CCL2 in both AD and CTE cases. Aβ
42 did not have any correlation on CCL2 in CTE cases; however, there was a negative correlation found between Aβ
42 and CCL2 in AD males. Overall, the present study expands on previous work demonstrating neuroinflammation and glial recruitment is a consequence of RHI and might be implicated in CTE pathogenesis [
2].
The current results suggest CCL2 is part of the neuroinflammatory signaling cascade after RHI. The initial mechanisms behind CCL2 elevation after head impacts may be protective. Recruiting microglia and monocytes to areas of damage is critical to remove dead tissue, prevent infection, and promote recovery. However, prolonged, chronic, or intense signaling turns the initial protective response into a damaging one. Consistent with chronic signaling through RHI, CCL2 was found to be correlated with the years spent playing American football. Additionally, CCL2 trended higher in the RHI without CTE group compared to controls suggesting the chronic exposure and the damage associated with playing American football is potentially sufficient to induce CCL2 in the brain, independent of pTau. After injury, brain derived microglia and peripheral-derived macrophages are commonly observed to be recruited to the region of damage. In CTE, the area of most concentrated RHI damage are blood vessels at the depths of the cortical sulcus in the frontal cortex [
6]. In agreement, elevated Iba1+ cells were seen to accumulate in correlation with perivascular deposits of pTau (i.e., the CTE pathognomonic lesion [
6]). Although the majority of accumulating cells were Iba1+/TMEM119+, a subset were TMEM119− and believed to be infiltrating peripheral macrophages, which has been previously reported after RHI [
8]. Future work will be needed to verify the peripheral macrophages involvement, as it is possible the TMEM119− population are microglia that downregulate the TMEM119 gene expression during inflammation. Although CCL2 was observed to correlate with both increased number of microglia and increased inflammatory activity, it is likely that CCL2 is only involved in the recruitment of cell and the glial inflammatory response occurs via secondary factors (i.e., proximity to damage neurons, pTau, or Aβ). To that end, multiple linear regression modeling demonstrated that when including Iba1, CD68, and age at death into the same model, only the Iba1+ cell density correlated with CCL2. This suggests that in the current study, CCL2 is only recruiting microglia to areas of damage.
Although the results suggest CCL2 and the neuroinflammatory response could be elevated prior to pTau accumulation, it is difficult to determine causality and the order of events due to the cross-sectional nature of studies using postmortem human tissue. However, regardless of which occurs first, our previous work suggests that once there is an increase in neuroinflammatory microglia, a feedback loop occurs where pTau causes inflammation which further induces pTau deposition [
2]. In addition to enhanced pTau deposition, the inflammatory response results in tissue damage [
31]. In experimental models, loss of CCR2 has been observed to block recruitment and reduce the area damaged suggesting a beneficial effect of limiting microglia and macrophages [
31]. Moreover, several studies have confirmed that blocking the CCL2 signaling pathway through genetic means or small molecules have potentially protective effects after head impacts [
32]. Considering these studies, future research should examine the possible beneficial effect of blocking microglia recruitment and its outcome on local neuroinflammation and pTau deposition.
In addition to blood vessels, the frontal cortex is where CTE pathology is typically first observed and the calcarine cortex is relatively spared [
6]. It is not entirely clear why the frontal cortex as opposed to the parietal or temporal cortex exhibits pathology first, but it hypothesized to be related to the physical area of contact (i.e., helmet to helmet hits) in addition to kinetics and physics of head impacts [
7,
33]. This would suggest that changes related to CTE pathology would initially be restricted to the region where pathology occurs first. Several studies have shown that CCL2 was elevated in the CSF after TBI [
34,
35]. However, tissue regional specificity of CCL2 in the brain has not been examined before. Here, we show that in low and high stage CTE, when standardizing frontal cortex CCL2 values to those in the calcarine cortex, more CCL2 was found in the DLFC. Ordinal regression also demonstrated a step-by-step increase from control cases, RHI without CTE, low CTE, and high CTE when controlling for age of death. This comparison provides compelling evidence that glial recruitment signals are directed to the regions of greatest injury and CTE pathology as opposed to a non-specific TBI-related brain-wide increase.
CCL2 can be produced as a consequence of a variety of stimuli. Although the present study focused on RHI, increases in CCL2 has been found in various neurodegenerative diseases and other injuries. To further explore how similar or different the CCL2 dynamics found after RHI were to other stimuli, subjects with AD without a history of RHI were examined. The inclusion of cases with AD allowed investigation into how factors such as aging or specific pathogenic proteins like pTau and Aβ could factor into CCL2 production independent of head impacts. Using multiple linear regression modeling, it was observed that pTau did correlate with CCL2 in both AD and CTE. Additionally, age was observed to correlate with CCL2 as well, demonstrating exposure to head impacts is not the only driving factor in CCL2 expression. This represents the diverse nature of the immune response with multiple stimuli converging on specific pathways. Neurons and microglia have significant cross-talk with a diverse range of receptors designed to maintain a homeostatic environment [
36]. Disruption of this crosstalk will lead to neuroinflammation. Head impacts and the subsequent neuronal damage represent one way to disrupt this normal homeostatic relationship. Additionally, pTau aggregation in neurons also induces neuronal dysfunction and damage, independent of RHI. This shows that although the stimulus is different, similar CCL2 increases are observed across multiple diseases. Although this limits CCL2s ability to be used as a specific biomarker for disease, it does suggest that CCL2 could be a general target for therapeutics that possibly might be effective across multiple disorders.
Surprisingly, Aβ levels were not found to correlate with CCL2. Aβ plaques are associated with a microgliosis and are a consistent feature of AD and variably present in CTE [
37]. However, our results demonstrated that CCL2 was significantly associated with pTau and not Aβ
42 in the overall group as well as in both CTE and AD groups examined separately. It is unclear why the Aβ results in the current study does not agree with reports, mainly using AD transgenic mouse models, suggesting CCL2 facilitates Aβ deposition [
38,
39]. One explanation is that many of the Aβ related studies are performed in an in vitro setting or murine models of disease and do not fully recapitulate the human in vivo system. An important distinction is that many transgenic mouse lines only express Aβ or pTau pathology in isolation, when the true human disease environment is much more complex. Similarly, the current study did not examine separate effects of soluble vs insoluble versions of both pTau and Aβ which likely drive different aspects of disease. Additionally, the current study only examines the neurodegenerative environment at the time of death. This snapshot in time does not capture early pathologic changes at the beginning of disease. It is possible early CCL2 activity does drive initial Aβ deposition, however, this effect subsides after several years when pathology is more severe. Interestingly, when separating the AD group by gender, a trend toward an inverse relationship was observed in males. This is consistent with the role microglia play in phagocytosing Aβ [
40]. In cases with a higher CCL2 signal, more microglia might be recruited to phagocytose plaques resulting in less Aβ. However, as previously mentioned, it is difficult to fully observe this effect when other pathogenic proteins, head impacts, and age also affect CCL2 levels. Further investigation into the possible unique effects of Aβ will be needed.
The current study is not the first examination into chemokines in CTE. Previous work has demonstrated the chemokine CCL11 was elevated in CTE [
26]. Furthermore, CCL11 was able to differentiate CTE and AD. An important distinction is that CCL11 was believed to be produced by the choroid plexus and not locally in areas of damage [
41]. Additionally, CCL11 has a broader range of action and can affect more diverse immune cell types, although it can also induce a glial inflammatory response [
42‐
45]. This represents the complex nature and interplay of the immune response and highlights the idea that no chemokine exists in isolation. Therefore, it will be important to examine how other chemokines act in concert with CCL2 and regulate glial recruitment and neuroinflammation in order to get a clear understanding of the neuroinflammatory cascade that occurs after head impacts.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.